More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/BLZ-945 [953769-46-5]
Chemical Structure
Chemical Structure
Chemical Structure

BLZ-945 [953769-46-5]

Research Use Only
AG-CR1-3609
AdipoGen Life Sciences
CAS Number953769-46-5
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>95%
Molecular Weight398.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    BLZ-945 [953769-46-5]
  • Delivery Days Customer
    10
  • CAS Number
    953769-46-5
  • Certification
    Research Use Only
  • Estimated Purity
    >95%
  • Molecular Formula
    C20H22N4O3S
  • Molecular Weight
    398.5
  • Scientific Description
    Anticancer compound. Orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R; c-Fms) inhibitor. More than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and platelet-derived growth factor receptor beta (PDGFRbeta). Selective against more than 200 additional kinases [2]. - Chemical. CAS: 953769-46-5. Formula: C20H22N4O3S. MW: 398.5. Anticancer compound. Orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R; c-Fms) inhibitor. More than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and platelet-derived growth factor receptor beta (PDGFRbeta). Selective against more than 200 additional kinases.
  • SMILES
    CNC(=O)C1=CC(OC2=CC=C3N=C(N[C@@H]4CCCC[C@H]4O)SC3=C2)=CC=N1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics: T. Wang, et al.; Int. J. Toxicol. 30, 300 (2011)
  • CSF-1R inhibition alters macrophage polarization and blocks glioma progression: S.M. Pyonteck, et al.; Nat. Med. 19, 1264 (2013)
  • CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells: D.C. Strachan, et al.; Oncoimmunology 2, e26968 (2013)
  • Therapeutically reeducating macrophages to treat GBM: C. Garris & M.J. Pittet; Nat. Med. 19, 1207 (2013)
  • Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite: J.A. Krauser, et al.; Xenobiotica 45, 107 (2015)